Abstract
Intrinsic or acquired chemoresistance represents the main obstacle to the successful treatment of cancer patients. Several mechanisms are involved in multidrug resistance: decreased uptake of hydrophilic drugs, increase of energy dependent efflux, alteration of the redox state, alteration of apoptotic pathways, and modification of the tumor microenvironment. In recent years, several types of nanoparticles have been developed to overcome these obstacles and improve the accumulation and release of drugs at the pathological site. In this review, we describe the main mechanisms involved in multidrug resistance and the nanovehicles which have been proposed to target specific aspects of this phenomenon.
Keywords: Cancer, chemoresistance mechanisms, drug delivery, miRNA/siRNA delivery, nanoparticles, mitoxantrone, daunorubicin.
Current Medicinal Chemistry
Title:Drug Delivery Nanoparticles in Treating Chemoresistant Tumor Cells
Volume: 24 Issue: 42
Author(s): Giuseppina Barrera, Martina Daga, Benedetta Ferrara, Chiara Dianzani, Stefania Pizzimenti, Monica Argenziano, Roberta Cavalli and Francesco Trotta*
Affiliation:
- Department of Chemistry, University of Turin, Via Pietro Giuria 7, 10125 Turin,Italy
Keywords: Cancer, chemoresistance mechanisms, drug delivery, miRNA/siRNA delivery, nanoparticles, mitoxantrone, daunorubicin.
Abstract: Intrinsic or acquired chemoresistance represents the main obstacle to the successful treatment of cancer patients. Several mechanisms are involved in multidrug resistance: decreased uptake of hydrophilic drugs, increase of energy dependent efflux, alteration of the redox state, alteration of apoptotic pathways, and modification of the tumor microenvironment. In recent years, several types of nanoparticles have been developed to overcome these obstacles and improve the accumulation and release of drugs at the pathological site. In this review, we describe the main mechanisms involved in multidrug resistance and the nanovehicles which have been proposed to target specific aspects of this phenomenon.
Export Options
About this article
Cite this article as:
Barrera Giuseppina, Daga Martina, Ferrara Benedetta, Dianzani Chiara, Pizzimenti Stefania, Argenziano Monica, Cavalli Roberta and Trotta Francesco*, Drug Delivery Nanoparticles in Treating Chemoresistant Tumor Cells, Current Medicinal Chemistry 2017; 24 (42) . https://dx.doi.org/10.2174/0929867323666161205122225
DOI https://dx.doi.org/10.2174/0929867323666161205122225 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cancer-Homing Toxins
Current Pharmaceutical Design Discovery of New Inhibitors of Urease Enzyme: A Study Using STD-NMR Spectroscopy
Letters in Drug Design & Discovery PI3K/Akt Signalling Pathway Specific Inhibitors: A Novel Strategy to Sensitize Cancer Cells to Anti-Cancer Drugs
Current Pharmaceutical Design Deregulation of the Akt Pathway in Human Cancer
Current Cancer Drug Targets Phenylbutyric Acid: Simple Structure - Multiple Effects
Current Pharmaceutical Design Subject Index to Volume 3
Current Medicinal Chemistry - Central Nervous System Agents Intracellular Delivery of Potential Therapeutic Genes: Prospects in Cancer Gene Therapy
Current Gene Therapy Estrogen and Female Lower Urinary Tract Dysfunction
Current Women`s Health Reviews Editorial Review 2017
Current Radiopharmaceuticals Arsenic trioxide Alters the MicroRNA Expression Profile of U87 glioblastoma
Anti-Cancer Agents in Medicinal Chemistry A Novel Marine Drug, SZ–685C, Induces Apoptosis of MMQ Pituitary Tumor Cells by Downregulating miR–200c
Current Medicinal Chemistry Unravelling the Genetic Susceptibility to Develop Ligament and Tendon Injuries
Current Stem Cell Research & Therapy Multiple Sclerosis: Current and Future Treatment Options
Endocrine, Metabolic & Immune Disorders - Drug Targets A Dual Mode Pulsed Electro-Magnetic Cell Stimulator Produces Acceleration of Myogenic Differentiation
Recent Patents on Biotechnology Biological Activities of QIAPI 1 as a Melanin Precursor and Its Therapeutic Effects in Wistar Rats Exposed to Arsenic Poisoning
Central Nervous System Agents in Medicinal Chemistry Polymer-clay Nanocomposites, Preparations and Current Applications: A Review
Current Nanomaterials Monitoring of Treatment-Induced Apoptosis in Oncology with PET and SPECT
Current Pharmaceutical Design Novobiocin and Additional Inhibitors of the Hsp90 C-Terminal Nucleotide- binding Pocket
Current Medicinal Chemistry Vitamin D - Pivotal Nutraceutical in the Regulation of Cancer Metastasis and Angiogenesis
Current Medicinal Chemistry Male Pelvic Pain: Beyond Urology and Chronic Prostatitis
Current Rheumatology Reviews